Background/Aim. Ventilator-associated pneumonia (VAP) incidence, causative pathogens, and resistance patterns are different among countries and intensive care units (ICUs). In Europe, resistant organisms have progressively increased in the last decade. However, there is a lack of data from Serbian ICUs. The aims of this study were to evaluate etiology and antimicrobial resistance for pathogens causing VAP in ICU patients, to examine whether there were differences among pathogens in early-onset and late-onset VAP and to identify mortality in patients with VAP after 30 and 60 days of hospitalization. Methods. A retrospective cohort study was conducted in the respiratory ICU and all adult patients diagnosed with VAP from 2009 to 2014 were included. Results. Gram negative organisms were the major pathogens (80.3%). The most commonly isolated was Acinetobacter spp (59.8%). There was a statistically significant increase in the incidence of infection with Klebsiella pneumoniae (8.9% vs 25.6%; p = 0.019). Extensively drugresistant strains (XDR) were the most common (78.7%). Late-
Introduction
Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in patients receiving mechanical ventilation. VAP remains a major cause of morbidity and mortality among critically ill patients and accounts for more than one-half of all antibiotic use in an Intensive Care Unit (ICU) 1 . The estimated incidence of VAP is 9% to 27%, with a mortality rate of 25% to 50% 2 . The appropriateness of empirical antimicrobial therapy for VAP is a key determinant of patient outcome 2 . Changes in pathogen distribution and patterns of antibiotic resistance complicate antibiotic treatment and care of the patients. Duration of mechanical ventilation was found to be one of the most important factors determining the composition of offending VAP pathogens 3 . Whereas early-onset VAP is more likely to be caused by antibiotic-sensitive bacteria, lateonset VAP is more likely to be caused by multi-drug resistant (MDR) pathogens. However, studies with opposite results were published recently [4] [5] [6] [7] , which showed that bacteriology of VAP may not follow a pattern of early versus late infection, particularly in patients that are at risk for MDR infections 8 .
The incidence of infection with specific pathogens with different susceptibility patterns causing VAP may not only vary from hospital to hospital but also within the same hospital or ICU over time 8 . This is the reason why empiric initial antibiotic treatment for VAP should be based on general guidelines, but also on up-to-date information on local epidemiology 8 . There is a lack of National registry consisting data from Serbian ICUs in regard to the local microbiological profile of pathogens causing VAP as well as to their antibiotic susceptibility and resistance patterns.
Given the scarcity of data, the primary aim of the present study was to evaluate etiology and antimicrobial resistance trends for nosocomial pathogens causing VAP in respiratory ICU patients and to examine whether there were differences among pathogens in early-onset and late-onset VAP. The aim of the study was also to identify mortality in patients with VAP after 30 and 60 days of hospitalization.
Methods

Study design
A retrospective cohort study was conducted in the 5-bed respiratory ICU of the Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica (Serbia). All adult patients diagnosed with VAP from January 2009 to December 2014, were included. This study was approved by the Hospital Ethics Committee. In order to evaluate changes in the incidence of infection with pathogens and changes in their resistance pattern, 6 year period was divided into two separate periods: period I (January 2009 to December 2011) and period II (January 2012 to December 2014).
Definitions
VAP was diagnosed in the presence of a new or persistent (≥ 48 hours) and progressive radiographic infiltrate plus at least 2 of the following: temperature of ≥ 38ºC or < 35ºC; purulent tracheal secretions or a change in characteristics of sputum; or leucocytosis (> 10.000 white blood cells/mm 3 ) or leucopenia (< 4.000 white blood cells/mm 3 ) 9, 10 . After clinical diagnosis of VAP had been established, quantitative culture of endotracheal aspirate (ETA) was performed to identify VAP pathogens. Only pathogens isolated at a concentration of > 10 6 colony-forming units (CFU/mL) was considered causative of VAP 9 . VAP was classified by the onset of the disease as early-onset VAP, which occurred within the first 4 days and late-onset VAP, which developed more than 4 days after starting mechanical ventilation (MV) 3 . If patients met clinical criteria for VAP, antibiotic therapy was initiated empirically according to primary diagnosis, comorbidities, prior antibiotic exposure, duration of the previous hospitalization of the patient, and the result of the surveillance cultures.
Multidrug resistance (MDR) was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Extensively drug-resistance (XDR) was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories). Pandrugresistance (PDR) was defined as non-susceptibility to all agents in all antimicrobial categories 11 . Standardized definitions were used to determine the presence or absence of ICU complications including acute respiratory distress syndrome (ARDS) 10 , severe sepsis and septic shock 12 .
Data collection
Demographic data, comorbidities, Charlson comorbidity score, Simplified Acute Physiology Score II (SAPS II), Acute Physiology and Chronic Health Evaluation II (APACHE II), the Sequential Organ Failure Assessment (SOFA) score at ICU admission, admission diagnosis of the patients, reason for endotracheal intubation, prior antibiotic use, microorganisms of VAP, antibiotic susceptibility, lengths of ICU and hospital stays and duration of MV prior to VAP onset were recorded. All patients were followed-up for survival status until 60 days after the initial onset of VAP or until death (if patients died within 60 days). The overall 30-day and 60-day mortalities were recorded. Only the first VAP episode was evaluated. 
Microbiology
Statistical analysis
Data entry and analysis were performed using IBM SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA). A descriptive analysis was used to investigate patient demographics and ICU data. The median with range was employed for not-normally distributed continuous variables, and mean ± standard deviation (SD) was used for normally distributed continuous variables. Numbers and percentages were used when applicable. The χ 2 test and Fisher's exact test were employed for testing differences in values of dichotomous variables among study groups, Kruskal-Wallis and Mann-Whitney U tests were used for continuous variables with not-normal distribution. The level of significance was set at p < 0.05.
Results
During the study period, 844 adult patients were admitted to the ICU. VAP developed in 144 (17%) patients during the ICU stay. Twenty two patients were excluded from the analysis (lack of data). So, the final analysis of bacterial etiology included 122 patients/ETA samples (78 males and 44 females) with 141 bacterial species isolated. The incidence of VAP was 47.3 cases per 1,000 ventilator days. The mean age of the patients was 56.8 ± 14.6 years. The most common comorbidities of the VAP patients were hypertension (50.8%), other cardiovascular diseases (41.8%) and the chronic obstructive pulmonary disease (COPD) (28.7%). The major reasons for intubation were as following: ARDS (39.3%), pneumonia (34.4%), cardiac arrest (8.2%), and exacerbation of COPD (6.6%). Clinical characteristics of analyzed patients on admission at ICU are shown in Table 1 .
Median length of ICU stay was 19 days (4-85) and of hospital stay 30 (4-112) days. Out of 122 patients that developed VAP, 50 (41.0%) died. The patients who did not survive after 60 days were significantly older than the patients who survived (60.6 ± 14.5 years and 53.2 ± 13.8 years respectively; p = 0.004). Monomicrobial infection occurred in 103 of 122 (84.4%) patients. Isolated pathogens and mortality rates are shown in Table 2 . Almost all isolate were bacteria; the fungal infection (Candida albicans) was reported in one patient and Stenotrophomonas maltophilia was isolated in one patient (0.8%) in this study (Table 2) .
Early-onset VAP was diagnosed in 23 patients (18.9%) and median of onset was 4 (2-4) days of mechanical ventilation. Late-onset VAP was diagnosed in 99 (81.1%) patients and median of onset was 9 (5-27) days of MV. Mortality after 30 days (47.8% vs 39.4%; p = 0.46) and 60 days (47.8% vs 49.5%; p = 0.89) was not different in patients with early-onset and late-onset VAP, respectively. The pattern of isolates according to the type of VAP is shown in Table 3 . Figure 1 demonstrates the proportion of drug susceptibility of each microorganism. 
MRSA -methicillin-resistant Staphylococcus aureus.
The resistance of all Acinetobacter isolates was high to piperacillin/tazobactam (99%), ciprofloxacin (97%), carbapenems (95% to imipenem and 96% to meropenem), ceftazidime (92%), cotrimoxazole (88%) and gentamicin (87%). Among the 4th generation of cefalosporins, the resistance was lower to cefepime (72%) and among aminoglycosides to netilmicin (67%). Acinetobacter spp was not tested for amikacin in 52 (58%) cases, however, all isolates which were tested (38/90) were resistant to amikacin (42%). Thirty six percent of Acinetobacter spp isolates were resistant to ampicillin-sulbactam. Monitoring of total resistance of isolates showed that there was no resistance to colistin, while resistance to tigecycline was 7%. Seventy three percent of Pseudomonas aeruginosa isolates were resistant to gentamicin, 67% to ciprofloxacin, 57% to meropenem, 55% to piperacillin, 42% to piperacillin/tazobactam, 52% to ceftazidime, 41% to amikacin, 38% to cefepime and 35% to imipenem. The highest resistance of Klebsiella pneumoniae (K. pneumoniae) was observed against β-lactams (100% isolates were resistant to ampicillin and 94% to ampicilin/sulbactam); among 3rd and 4th generation cephalosporins 93% isolates were resistant to ceftriaxone, 89% to cefotaxime, 94% to ceftazidime and cefepime), and then against ciprofloxacin (94%) and cotrimoxazole (93%). However, it was relatively less resistant to piperacillin-tazobactam (47%), gentamicin (44%) and amikacin (22%). Among carbapenems, 38% isolates were resistant to ertapenem, 11% to imipenem and 11% to meropenem. In methicillin-resistant Staphylococcus aureus (MRSA) isolates no resistance was observed against vancomycin, teicoplanin and linezolid. There were no differences in the incidence of infection with Acinetobacter spp, Pseudomonas aeruginosa and MRSA between period I (2009-2011) and period II (2012-2014), but there was a statistically significant increase in incidence of infection with K. pneumoniae from 8.9% in period I to 25.6% in period II (p = 0.019). A significant increase in resistance rates of Acinetobacter spp to ampicillin/sulbactam in period II (2012-2014) was also found (30.2% vs 58.6%; p = 0.01).
The resistance of Acinetobacter spp to other tested antibiotics did not change significantly between the two studied periods. The resistance of Pseudomonas aeruginosa to cefepime, piperacillin/tazobactam and amikacin increased between the two studied periods, without a statistically significant difference, but it increased significantly to imipenem (20% vs 71.4% respectively; p = 0.052). The resistance of K. pneumoniae increased, especially to carbapenems (ertapenem: 0% vs 54.5%; p = 0.09), but due to the small sample statistical significance could not be detected. During the two studied periods there was no difference in incidence of infection with XDR (75.9% vs 83.7%; p = 0.317) and MDR strains (19% vs 14%; p = 0.482) in all isolated bacteria.
Discussion
Multiresistant bacteria pose a great threat and challenge in everyday clinical practice. That is why regular monitoring of susceptibility of isolated bacteria to antibiotics in each ICU is essential. These data, as well as data regarding patient's characteristics on admission to ICU will help determine the most efficient empirical therapy for VAP. Empirical therapy based on data on local resistance has an impact on lowering morbidity and mortality, shortening of hospitalization, lowering of treatment expenses, and prevents the development of MDR bacteria in patients with VAP 13, 14 . The overall incidence of VAP was 47.3 per 1,000 ventilator-days. The incidence rate of VAP ranges from 13.2 to 51 per 1,000 ventilator days 9 . In a study performed in surgical and medical ICUs in a tertiary hospital in China it was found that the incidence of VAP in the medical ICU was 29.7 cases per 1,000 ventilator days 15 . Differences in infection control practices and lack of established infection control programs may account for higher rates.
VAP caused mortality varies (25%-50%) and greater mortality has been noticed in infections caused by Pseudomonas and Acinetobacter, in medical ICUs compared to surgical ones, and with the administration of inadequate empirical antibiotic therapy 3 . In our study, mortality in patients with VAP was 41.0% after 30 days, and 49.2 % after 60 days. In a study by Song et al. 15 mortality in VAP patients in medical ICU was 41.9% after 30 days, and 53.5% after 60 days. One of the significant characteristics of our patients on admission to ICU was a high incidence of ARDS (43.7%). A number of clinical studies have shown that pulmonary infection is very frequent in patients with ARDS (34-70%) and often leads to sepsis, multiorgan dysfunction and death 16 . In a study by Forel et al. 17 , mortality in patients with ARDS and VAP was 41.8%.
According to American Thoracic Society, empirical antibiotic therapy in VAP treatment should be based on VAP onset time (early-onset vs late-onset VAP) and on the presence of the risk factors for the development of MDR bacteria 3 . In our study, most of the patients had late-onset VAP (81.1%) and there was no difference among pathogens causing early-onset and late-onset VAP. These results were expected since most of our patients had a number of risk factors which predispose to the colonization with MDR bacteria (69.3% of patients had received antibiotic treatment prior to admission, 82% was previously hospitalized). Evidence suggests that resistance is a problem also in patients with early-onset VAP is growing. In a study conducted in Serbia in multidisciplinary ICU, no difference was shown among isolated bacteria in patients with early-onset and lateonset VAP 18 . It is interesting that prospective multicenter study in 27 ICUs in 9 European countries showed that even in patients who do not have classic risk factors for MDR bacteria, in 50.7% VAP was caused by multiresistant bacteria 5 . These results speak in favor of the fact that microbiology does no longer follow model "early-onset vs late-onset VAP" what presents a new problem for empirical therapy 19 . Our study also showed there was no difference in mortality in patients with early-onset and late-onset VAP after 30 days and 60 days suggesting that VAP onset time is not mortality predictor. Other researchers who compared mortality in patients with early-onset and late-onset pneumonia, came to the similar results [20] [21] [22] [23] . In our study, gram negative bacteria were the main pathogens of VAP (80.3%) which is in correlation with the results from other recently published studies, especially from the developing countries. In a study by Chittawatanarat et al. 24 gram negative bacteria caused VAP in 94.7% of cases. During the past ten years, the significance of Acinetobacter spp has increased due to the rapid spreading of the strains resistant to the most of the antibiotics, which was noticed throughout the world 25 . One of the important features of Acinobacter baumannii (A. baumannii) is its ability to survive for a longer time period on the surfaces around patient from where is transmitted to patients in the direct or indirect way. In our study, Acinetobacter spp was the most frequent VAP pathogen (59.8%), and the most common XDR strain (89%). Studies in Asian countries have shown that A. baumanii was the most frequent pathogen in mixed medical-surgical ICUs where the incidence of infection was between 25% and 50% 24, 26 . In the neighboring countries, a high incidence of infection with MDR A. baumannii (85.6%) and XDR (14.4%) was also noticed 27 . Having in mind risk factors for infections caused by multiresistant Acinetobacter spp (ARDS, septic shock, severity of the disease, previous use of broad spectrum antibiotics, previous hospitalisation, duration of ICU stay and contamination of patient's surroundings) 28, 29 , significant presence of Acinetobacter spp in our ICU (frequency of ARDS -43.7% and septic shock on admission -36.1%, previous antibiotic therapy -69.3%, previous hospitalisation -82%) can be partially explained. Although carbapenems are considered to be a basic therapy in the treatment of A. baumannii, during the last years reporting of strains resistant to carbapenems is increased throughout the world 30 . In our study, Acinetobacter spp showed a high degree of resistance to carbapenems (more than 95%). According to the Annual Report of the European Antimicrobial Resistance Surveillance Network for 2014, resistance to carbapenems was from 0% (the Netherlands) to 93.2% (Greece) 31 . Šuljagić et al. 32 in their study analyzed and compared the surveillance data on Acinetobacter spp nosocomial colonization/infection collected during the wartime with the data collected in peacetime in surgical clinics of the Military Medical Academy in Belgrade (Serbia). Their data showed that resistance of Acinetobacter spp to imipenem was 0% during wartime (1999) and 18.6% during peacetime (2001), and to meropenem 4.6% and 27.1%, respectively. Having in mind these data, pronounced increase of Acinetobacter spp resistance to carbapenems in our region during the last 15 years is obvious. In the study by Šuljagić et al. 32 Acinetobacter spp resistance to ampicillin/sulbactam was 30% what is similar to the results of our study. However, in our study the significant increase of resistance to ampicillin/sulbactam was noticed between two study periods (30.2% vs 58.6%; p = 0.012). The increase of resistance was also marked in the neighboring countries. In Croatia, resistance of Acinetobacter spp to ampicillin/sulbactam increased from 13% (2009) to 19% (2012) 33 . In our ICU resistance to colistin was not detected, although it was noticed during the last years in Europe (4%), and countries with the highest resistance to colistin were Greece and Italy
31
. The assumed reason that resistance to colistin was not detected in this study is that the colistin was just approved in Serbia for hospital use in 2013, and in this paper data analyzed was ending with the year 2014.
In our study the resistance of Pseudomonas aeruginosa to piperacillin/tazobactam, ciprofloxacin, ceftazidime and aminoglycosides was high in comparison with the latest data on resistance in other European countries. The highest resistance of Pseudomonas aeruginosa was marked in Romania (62.2% to piperacillin/tazobactam, 55.4% to ciprofloxacin, 59.1% to ceftazidime, 63.4% to aminoglycosides), and the lowest in Denmark, Iceland and Luxembourg (0%-4.4%) 31 . Besides, the resistance of Pseudomonas aeruginosa to imipenem was grown significantly between the two studied periods. The trend of resistance increase to carbapenems from 2011 to 2014 was also noticed in Germany, Hungary and Slovakia 31 . In our study significant increase in the incidence of infection with K. penumoniae as a pathogen of VAP between the two study periods was noticed (3.8% vs 16.3%; p = 0.02). This increase was due to the statistically significant increase of XDR strain of K. pneumoniae (3.8% vs 14.0%; p = 0.040). For the first time, XDR strain of K. pneumoniae (sensitive only to aminoglycosides and carbapenems) was noticed in December 2010. The resistance of K. pneumoniae has also increased to imipenem, meropenem i ertapenem between the two studied periods (0% vs 18.2%; 18.2% vs 54.5%, respectively), but statistically significant difference could not be detected. The three European countries with the highest marked resistance to carbapenems in 2014 were Greece (62.3%), Italy (32.9%) and Romania (31.5%). In these countries the greatest percent of K. pneumoniae resistant to polymyxins was noticed, indicating that the situation is very worrying 31 .
All cases of MRSA caused VAP (5/122) were marked in 2009 and all were sensitive to linezolid and vancomycin. Reports from other European countries also show a decrease of MRSA from 2011 to 2014 from 18.6% to 17.4%, respectively 31 . Empirical treatment of VAP with the high probability of MDR pathogens is one of the greatest challenges met by the intensive care specialists. Having in mind the results of our study, adequate empirical therapy of VAP would be colistin (because of the high prevalence of XDR Acinetobacter spp) plus imipenem (because of Pseudomonas aeruginosa and K. pneumoniae) plus vancomycin (because of MRSA). But, due to the increased use of colistin PDR strains of Acinetobacter spp can develop, and that is why its use must be rational 29 .
After the short duration of broad spectrum antibiotic therapy and after the antibiogram is obtained, quick deescalation of antibiotic therapy should follow 34 .
The significance of this study is in a long monitoring period and therefore obtaining insight in resistance changes of VAP pathogens during the time. Besides, this is the first analysis of VAP pathogens in our ICU.
There are several limitations of this study. The first one is that the bacterial isolates from the VAP cases may not reflect the true etiologic pathogens because more specific diagnostic procedures, such as bronchoalveolar lavage, were not performed. The second limitation is that it was performed in one ICU of the tertiary health facility specialized in treating pulmonary patients. Therefore, the microbiological profile of the isolated strains of VAP pathogens reflects the local epidemiologic situation and it can not be extrapolated to other centres. That is why multicentric research that would help forming general recommendation is necessary. Also, it is necessary to continue regular monitoring of microbiological profile and susceptibility of the pathogens in our ICU in order to timely detect changes, especially today when PDR strains are marked in southeast Europe.
Conclusion
According to results obtained in this study, gram negative bacteria were the main pathogens of ventilator associated pneumonia, out of which the most common was XDR strain of Acinetobacter spp with a high resistance to all tested antibiotics except for colistin and tigecycline. There was no difference in pathogens in patients with early-onset and lateonset ventilator associated pneumonia. Mortality in patients with VAP was 41.0% after 30 days and 49.2 % after 60 days of hospitalization, and there was no difference in mortality between patients with early-onset and late-onset VAP.
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